NASDAQ$ENGN
enGene Therapeutics Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported financial results for the third quarter ended July 31, 2024.
enGene Holdings Inc. announced its financial results for the third quarter ended July 31, 2024. The company's cash and cash equivalents were $257.7 million as of July 31, 2024, and expects this to fund operations into 2027. Net loss attributable to common shareholders was approximately $14.1 million, or $0.32 per share.
- Cash and cash equivalents of $257.7 million provide runway into 2027.
- Total operating expenses were $16.8 million for the three months ended July 31, 2024, compared to $6.2 million for the three months ended July 31, 2023.
- Net loss attributable to common shareholders was approximately $14.1 million, or $0.32 per share, compared to approximately $6.0 million, or $8.55 per share, for the same period for the three months ended July 31, 2023.
- Company remains on track to report preliminary LEGEND data in September 2024
Headline financials
Revenue & EPS history
Engene · Revenue · Quarterly
$0
Forward guidance
enGene expects to release preliminary data from the LEGEND study’s pivotal BCG-unresponsive cohort by the end of September and expects that its existing cash and cash equivalents will fund operating expenses, debt obligations and capital expenditures into 2027.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports · overlaid with Q3 2024
-2.6%
Avg return
Earnings day
-1.6%
Avg return
5 days after
+17.4%
Avg return
30 days after
43%
6 / 14 earnings
Positive
+5.3%
Q4 2025
Best reaction
-18.9%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | -18.9% | -17.5% | -15.8% | |
| Q4 2025 | +5.3% | +8.3% | +21.3% | |
| Q3 2025 | -6.3% | +7.6% | +38.4% | |
| Q2 2025 | -0.9% | +0.9% | +2.8% | |
| Q1 2025 | +4.9% | -10.1% | -22.3% | |
| Q4 2024 | -1.7% | +6.6% | +20.4% | |
| Q3 2023 | +1.8% | +1.7% | +4.3% | |
| Q3 2024 | +1.8% | +1.7% | +4.3% | |
| Q2 2024 | -13.5% | -16.4% | -9.3% | |
| Q2 2023 | -13.5% | -16.4% | -9.3% | |
| Q1 2024 | +4.9% | +5.2% | -1.6% | |
| Q1 2023 | +4.9% | +5.2% | -1.6% | |
| Q4 2023 | -2.7% | +0.5% | +106.1% | |
| Q4 2022 | -2.7% | +0.5% | +106.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro